AS PER Invoice Brazil Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: AS PER Invoice Brazil Pharmaceutical Import Records from India — 2 Products, $206.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AS PER Invoice Brazil — Pharmaceutical Importer Profile (2026) | 2 Products, $206.0K Trade | TransData Nexus

AS PER Invoice Brazil

Pharmaceutical Importer · Brazil · Biologics & Immunotherapy Focus · $206.0K Total Trade · DGFT Verified

AS PER Invoice Brazil is a pharmaceutical importer based in Brazil with a total trade value of $206.0K across 2 products in 2 therapeutic categories. Based on 62 verified import shipments from Indian Customs (DGFT) records, AS PER Invoice Brazil is the #1 buyer in 2 products including Ustekinumab, Daratumumab. AS PER Invoice Brazil sources from 2 verified Indian suppliers, with Vama Lifecare Private Limited accounting for 99.5% of imports.

AS PER Invoice Brazil — Import Portfolio & Supplier Network

AS PER Invoice Brazil import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to AS PER Invoice Brazil?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vama Lifecare Private Limited	$521.7K	160	99.5%
Melon Globalcare	$2.7K	6	0.5%

AS PER Invoice Brazil sources from 2 verified Indian suppliers across .

What Formulations Does AS PER Invoice Brazil Import?

Formulation	Value	Ships
Harmless medicine for human consumption trastuzumab deruxtecan 100 MG per vial batch number.: 418342	$60.2K	7
Harmless medicine for human consumption INJ. trastuzumab deruxtecan 100 MG batch number.: 418342	$42.2K	6
Harmless medicine for human consumption daratumumab liquid for injection 1800 MG batch number.: pfs2f13	$39.5K	4
Harmless medicine for human consumption INJ. daratumumab concentratefor solution for infusion 400 MG/20 ML	$26.6K	2
Harmless medicine for human consumption ustekinumab solution for injection 90 MG batch number.: pgs07mb.b	$17.9K	6
Harmless medicine for human consumption INJ trastuzumab deruxtecan 100 MG batch number 418342	$17.5K	2
Harmless medicine for human consumption ustekinumab solution for injection 90 MG batch number.: pgs07mb.a	$16.9K	7
Harmless medicine for human consumption batch number.: b400220 manufacturing date.: 04/2024 expiry date.	$11.4K	2
Harmless medicine for human consumption daratumumab liquid for injection 1800 MG batch number.: pks1f01	$10.8K	1
Harmless medicine for human consumption INJ. ustekinumab solution for injection 90 MG batch number.	$10.4K	3
Harmless medicine for human consumption ustekinumab solution for injection 90 MG batch number pis3bmi	$10.1K	7
Harmless medicine for human consumption ustekinumab solution for injection 90 MG batch number.: pis16mb.a	$10.1K	8
Harmless medicine for human consumption daratumumab liquid for injection 1800 MG batch number pks1f01	$9.7K	1
Harmless medicine for human consumption trastuzumab deruxtecan 100 MG per vial (enhertu 100 MG per vial)	$9.5K	1
Harmless medicine for human consumption INJ vedolizumab 300 MG batch number 12791127 manufacturing	$9.4K	2

AS PER Invoice Brazil imports 92 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ustekinumab	Biologics & Immunotherapy	$112.2K	50	8.8%	1
2	Daratumumab	Advanced Oncology	$93.8K	12	7.0%	1

AS PER Invoice Brazil imports 2 pharmaceutical products across 2 categories into Brazil totaling $206.0K. The company is the #1 buyer for 2 products: Ustekinumab, Daratumumab.

AS PER Invoice Brazil — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

AS PER Invoice Brazil is a pharmaceutical importer based in Brazil, specializing in the acquisition of finished pharmaceutical formulations from international suppliers, particularly from India. The company operates as a buyer, sourcing a range of pharmaceutical products to meet the demands of the Brazilian market. While specific details about its headquarters and parent company are not publicly disclosed, AS PER Invoice Brazil plays a significant role in the distribution of imported pharmaceutical products within Brazil. Its operations are crucial in bridging the supply of international pharmaceutical products with the needs of the Brazilian healthcare system.

2Distribution Network

Specific information regarding AS PER Invoice Brazil's warehouse locations and logistics capabilities is not publicly available. However, as a pharmaceutical importer, the company is likely to have established distribution networks within Brazil to facilitate the efficient delivery of imported pharmaceutical products. These networks would be designed to ensure timely and compliant distribution across the country, adhering to Brazil's regulatory requirements for pharmaceutical imports.

3Industry Role

AS PER Invoice Brazil functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from international suppliers, notably from India. The company's role is pivotal in introducing and distributing these imported products within the Brazilian market, thereby contributing to the diversity and availability of pharmaceutical options for healthcare providers and patients in Brazil.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — AS PER Invoice Brazil

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

AS PER Invoice Brazil's sourcing strategy exhibits a high degree of concentration, with a total import value of $206,000 USD from India across 62 shipments, primarily from two suppliers: VAMA LIFECARE PRIVATE LIMITED and MELON GLOBALCARE. VAMA LIFECARE PRIVATE LIMITED accounts for 99.5% of the shipments, indicating a dominant supplier relationship. This concentration suggests a strategic choice to maintain a streamlined supply chain, potentially benefiting from established relationships and consistent product quality. However, such dependency also introduces risks related to supply chain disruptions, pricing fluctuations, and potential regulatory changes affecting the primary supplier. The stability of this relationship is crucial for AS PER Invoice Brazil's operations, and any changes in the supplier's circumstances could significantly impact the company's ability to meet market demands.

2Supply Chain Resilience

The resilience of AS PER Invoice Brazil's supply chain is closely tied to its reliance on a limited number of suppliers, particularly VAMA LIFECARE PRIVATE LIMITED. This concentrated sourcing strategy may pose challenges in terms of supply chain flexibility and responsiveness to market changes. The company's ability to diversify its supplier base and establish relationships with additional suppliers could enhance its supply chain resilience, mitigating risks associated with over-reliance on a single source. Additionally, ensuring that suppliers comply with international Good Manufacturing Practices (GMP) standards is essential for maintaining product quality and regulatory compliance.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the primary regulatory authority overseeing pharmaceutical products is the Brazilian Health Regulatory Agency, known as Anvisa (Agência Nacional de Vigilância Sanitária). Anvisa is responsible for the regulation and supervision of health-related products and services, including the authorization of clinical trials, active pharmaceutical ingredients (APIs), and the marketing authorization of drugs and biological products. The regulatory framework governing pharmaceutical imports into Brazil is comprehensive, encompassing various categories of drugs such as new synthetic and semi-synthetic drugs, generic drugs, similar drugs (branded generics), and biologic products. Each category is subject to specific regulations and guidelines to ensure safety, efficacy, and quality. For instance, the review time for marketing authorization applications is 120 days for dossiers granted priority review and 365 days for ordinary reviews, as stipulated by Law 6360/1973. These regulations are designed to align with international standards, ensuring that approved drugs meet rigorous safety and efficacy criteria. (gov.br)

2Import Licensing & GMP

Import licensing in Brazil requires that foreign companies have a legally constituted partner in Brazil responsible for marketing authorization, importing, distribution, and post-marketing surveillance within the country. This partnership is essential for navigating the regulatory landscape and ensuring compliance with Brazilian laws. Regarding Good Manufacturing Practices (GMP), Brazil recognizes certifications from reputable international bodies, including the European Union's GMP, the World Health Organization's GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are crucial for ensuring that imported pharmaceutical products meet the quality standards required by Anvisa. Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of pharmaceutical products within Brazil, ensuring that all parties in the supply chain adhere to established regulatory standards. (gov.br)

AS PER Invoice Brazil — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

AS PER Invoice Brazil's focus on importing biologics and immunotherapy products, particularly Ustekinumab and Daratumumab, indicates a strategic alignment with the growing demand for advanced treatments in Brazil. The substantial import values of $112,000 USD for Ustekinumab and $94,000 USD for Daratumumab underscore the market's need for these therapies. The company's portfolio concentration in these products suggests a targeted approach to meet the therapeutic needs of the Brazilian population, especially in the fields of immunology and oncology. This strategy positions AS PER Invoice Brazil to address critical health challenges and capitalize on the expanding market for specialized medical treatments.

2Sourcing Profile

AS PER Invoice Brazil's sourcing strategy is heavily concentrated on finished pharmaceutical formulations from India, with a particular emphasis on biologics and immunotherapy products. This focus aligns with the company's product strategy and the therapeutic needs of the Brazilian market. The reliance on a limited number of suppliers, notably VAMA LIFECARE PRIVATE LIMITED, indicates a preference for established relationships and consistent product quality. However, this concentration also highlights the potential risks associated with supplier dependency, emphasizing the need for strategic planning to ensure supply chain resilience and continuity.

Market Positioning

Seller's Guide — How to Become a Supplier to AS PER Invoice Brazil

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with AS PER Invoice Brazil, especially those offering high-quality biologics and immunotherapy products. The company's concentrated sourcing pattern suggests that introducing alternative suppliers could provide competitive advantages and mitigate risks associated with over-reliance on a single source. Potential gaps in AS PER Invoice Brazil's current sourcing include the need for diversification in supplier relationships and the introduction of additional product formulations to meet the evolving demands of the Brazilian market.

2Requirements & Qualifications

Indian exporters seeking to supply AS PER Invoice Brazil must ensure that their products comply with Anvisa's regulatory requirements, including obtaining the necessary marketing authorizations and adhering to Good Manufacturing Practices (GMP) recognized by Anvisa. Additionally, products must meet labeling requirements, including Portuguese language labeling and serialization mandates. Establishing a partnership with a legally constituted entity in Brazil is essential for navigating the import process and ensuring compliance with local regulations.

How to Approach

Frequently Asked Questions — AS PER Invoice Brazil

What products does AS PER Invoice Brazil import from India?

AS PER Invoice Brazil imports 2 pharmaceutical products across 2 categories. Top imports: Ustekinumab ($112.2K), Daratumumab ($93.8K).

Who supplies pharmaceuticals to AS PER Invoice Brazil from India?

AS PER Invoice Brazil sources from 2 verified Indian suppliers. The primary supplier is Vama Lifecare Private Limited (99.5% of imports, $521.7K).

What is AS PER Invoice Brazil's total pharmaceutical import value?

AS PER Invoice Brazil's total pharmaceutical import value from India is $206.0K, based on 62 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does AS PER Invoice Brazil focus on?

AS PER Invoice Brazil imports across 2 categories. The largest: Biologics & Immunotherapy (54.5%), Advanced Oncology (45.5%).

Get Full AS PER Invoice Brazil Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.